Current Atherosclerosis Reports

Papers
(The TQCC of Current Atherosclerosis Reports is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Revascularization Options for Left Main Disease: What Clinicians Need to Know130
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?77
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?76
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions76
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management66
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis60
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment59
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?53
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?52
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management51
The Effects of FABP4 on Cardiovascular Disease in the Aging Population50
Ambient Air Pollution and Atherosclerosis: Recent Updates48
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–202047
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators47
Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease (MINOCA): a Review of the Present and Preview of the Future46
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women44
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond40
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice39
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm38
The Genetic Basis of Hypertriglyceridemia37
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease36
Inflammation in the Peri-ACS Period: Ready for Prime Time?34
The Emerging Specialty of Cardio-Rheumatology34
Percutaneous Coronary Interventions in Women33
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?32
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women30
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention30
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?30
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review29
RNA Silencing in the Management of Dyslipidemias29
Myeloid Cells in Abdominal Aortic Aneurysm29
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?29
Lipoprotein(a): from Causality to Treatment29
Is There a Role of Coronary CTA in Primary Prevention? Current State and Future Directions28
Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease28
Hypertension in Women Across the Lifespan28
The Role of Sleep in Cardiovascular Disease28
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion27
Transgender Cardiovascular Health: Practical Management for the Clinician27
Low LDL-C: Is It all Good News?25
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger25
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know24
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment24
Childhood Hypertriglyceridemia: Is It Time for a New Approach?24
Update on Plant-Based Diets and Cardiometabolic Risk24
Importance of Nutrition Security to CVD Prevention Efforts in the USA24
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis23
Correction to: High-Density Lipoproteins and Serum Amyloid A (SAA)22
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis22
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?22
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease22
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?21
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?20
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?20
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?20
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review20
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity19
Lipoprotein (a): Recent Updates on a Unique Lipoprotein19
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference19
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor19
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease19
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction19
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis18
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know18
Is There a Role for Imaging Youth at Risk of Atherosclerosis?18
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine18
Gene Regulatory Networks in Coronary Artery Disease18
Cardiovascular Health and Disease in the Pakistani American Population17
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population17
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field16
Targeting the Gut Microbiome to Treat Cardiometabolic Disease16
Natural Sirtuin1 Activators and Atherosclerosis: an Overview16
Bempedoic Acid: for Whom and When16
What Causes Premature Coronary Artery Disease?16
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?15
Utility of FFRCT in Patients with Chest Pain15
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men15
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins15
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician15
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned15
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults15
Fixed Combination for the Treatment of Dyslipidaemia14
Apheresis: What Should a Clinician Know?14
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments14
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms14
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk14
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk14
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach14
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis14
Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease14
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults13
Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes13
0.077887058258057